Previous Close | 1.3650 |
Open | 1.3500 |
Bid | 1.3300 x 200 |
Ask | 1.4400 x 200 |
Day's Range | 1.2800 - 1.4299 |
52 Week Range | 0.7700 - 14.0000 |
Volume | |
Avg. Volume | 4,062,829 |
Market Cap | 2.329M |
Beta (5Y Monthly) | 1.52 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -8.9800 |
Earnings Date | Mar 28, 2024 - Apr 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.00 |
Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the Company originally issued in October 2023
New patent strengthens Adial’s patent portfolio and covers AD04’s unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorderCHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,905,562 was issue